Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Lif...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 Apr 2019
|
| In: |
Leukemia and lymphoma
Year: 2019, Jahrgang: 60, Heft: 11, Pages: 2705-2711 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428194.2019.1602262 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/10428194.2019.1602262
|
| Verfasserangaben: | Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, & Pauline Brice |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694664996 | ||
| 003 | DE-627 | ||
| 005 | 20220818042227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200416s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2019.1602262 |2 doi | |
| 035 | |a (DE-627)1694664996 | ||
| 035 | |a (DE-599)KXP1694664996 | ||
| 035 | |a (OCoLC)1341315259 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Tresckow, Bastian von |d 1977- |e VerfasserIn |0 (DE-588)130370932 |0 (DE-627)500426538 |0 (DE-576)298155087 |4 aut | |
| 245 | 1 | 0 | |a Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma |c Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, & Pauline Brice |
| 264 | 1 | |c 23 Apr 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 520 | |a In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts.Clinicaltrials.gov identifier: NCT02453594. | ||
| 650 | 4 | |a Classical Hodgkin lymphoma | |
| 650 | 4 | |a health-related quality-of-life | |
| 650 | 4 | |a KEYNOTE-087 | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a pembrolizumab | |
| 700 | 1 | |a Fanale, Michelle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ardeshna, Kirit M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chen, Robert W. |e VerfasserIn |0 (DE-588)1132835275 |0 (DE-627)888133286 |0 (DE-576)489018351 |4 aut | |
| 700 | 1 | |a Meißner, Julia |e VerfasserIn |0 (DE-588)1236765966 |0 (DE-627)176254850X |4 aut | |
| 700 | 1 | |a Morschhauser, Franck |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moskowitz, Craig H. |e VerfasserIn |0 (DE-588)1132835313 |0 (DE-627)888133324 |0 (DE-576)489018335 |4 aut | |
| 700 | 1 | |a Zinzani, Pier Luigi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Giezek, Hilde |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balakumaran, Arun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vo, Thao T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rauthe, Monika Sabine |d 1978- |e VerfasserIn |0 (DE-588)134040651 |0 (DE-627)55957598X |0 (DE-576)300272472 |4 aut | |
| 700 | 1 | |a Brice, Pauline |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 60(2019), 11, Seite 2705-2711 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma |
| 773 | 1 | 8 | |g volume:60 |g year:2019 |g number:11 |g pages:2705-2711 |a Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428194.2019.1602262 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200416 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1236765966 |a Meißner, Julia |m 1236765966:Meißner, Julia |d 910000 |d 910100 |e 910000PM1236765966 |e 910100PM1236765966 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1694664996 |e 3624024353 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1694664996"],"doi":["10.1080/10428194.2019.1602262"]},"title":[{"title_sort":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma","title":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma"}],"recId":"1694664996","note":["Gesehen am 16.04.2020"],"language":["eng"],"origin":[{"dateIssuedDisp":"23 Apr 2019","dateIssuedKey":"2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Bastian von Tresckow, Michelle Fanale, Kirit M. Ardeshna, Robert Chen, Julia Meissner, Franck Morschhauser, Craig Moskowitz, Pier Luigi Zinzani, Hilde Giezek, Arun Balakumaran, Thao T. Vo, Monika Raut, & Pauline Brice"]},"person":[{"role":"aut","display":"Tresckow, Bastian von","given":"Bastian von","family":"Tresckow","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Fanale","display":"Fanale, Michelle","role":"aut","given":"Michelle"},{"family":"Ardeshna","roleDisplay":"VerfasserIn","given":"Kirit M.","role":"aut","display":"Ardeshna, Kirit M."},{"roleDisplay":"VerfasserIn","family":"Chen","role":"aut","display":"Chen, Robert W.","given":"Robert W."},{"family":"Meißner","roleDisplay":"VerfasserIn","given":"Julia","display":"Meißner, Julia","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Morschhauser","role":"aut","display":"Morschhauser, Franck","given":"Franck"},{"family":"Moskowitz","roleDisplay":"VerfasserIn","given":"Craig H.","role":"aut","display":"Moskowitz, Craig H."},{"family":"Zinzani","roleDisplay":"VerfasserIn","display":"Zinzani, Pier Luigi","role":"aut","given":"Pier Luigi"},{"roleDisplay":"VerfasserIn","family":"Giezek","display":"Giezek, Hilde","role":"aut","given":"Hilde"},{"role":"aut","display":"Balakumaran, Arun","given":"Arun","family":"Balakumaran","roleDisplay":"VerfasserIn"},{"given":"Thao T.","display":"Vo, Thao T.","role":"aut","roleDisplay":"VerfasserIn","family":"Vo"},{"family":"Rauthe","roleDisplay":"VerfasserIn","role":"aut","display":"Rauthe, Monika Sabine","given":"Monika Sabine"},{"family":"Brice","roleDisplay":"VerfasserIn","given":"Pauline","role":"aut","display":"Brice, Pauline"}],"relHost":[{"recId":"324746237","pubHistory":["1.1989/90 -"],"id":{"issn":["1029-2403"],"zdb":["2030637-4"],"eki":["324746237"]},"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}],"disp":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphomaLeukemia and lymphoma","note":["Gesehen am 08.09.15"],"origin":[{"dateIssuedDisp":"1989-","publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2019","pages":"2705-2711","text":"60(2019), 11, Seite 2705-2711","issue":"11","volume":"60"}}]} | ||
| SRT | |a TRESCKOWBAPATIENTREP2320 | ||